



# Biotech Daily

Tuesday July 16, 2013

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH UP: GENETIC TECHNO UP 12%, IMPEDIMED DOWN 13%**
- \* **COMPUMEDICS \$285k FRENCH GRANT, APPOINTS GERMAN SALES REP**
- \* **MEDICAL AUSTRALIA VOTES FOR MEDIVET MERGER, CONSOLIDATION**
- \* **OBJ, GSK STUDY OF ELECTROMAGNETIC TOOTHBRUSH**
- \* **EU APPROVES BIONICHE FOLLTROPIN COW STIMULANT**
- \* **CELLMID APPOINTS JILLIAN MCGREGOR JOINT COMPANY SECRETARY**

## MARKET REPORT

The Australian stock market edged up 0.1 percent on Tuesday July 16, 2013 with the S&P ASX 200 up 4.9 points to 4,986.0 points.

Fifteen of the Biotech Daily Top 40 stocks were up, 12 fell, seven traded unchanged and six were untraded.

Genetic Technologies was the best, up one cent or 11.8 percent to 9.5 cents with 183,960 shares traded.

Atcor climbed 8.2 percent; Patrys was up 7.7 percent; Alchemia, Anteo and Ellex were up more than six percent; Allied Health was up 5.8 percent; Cellmid was up 3.1 percent; Clinuvel and Osprey rose more than two percent; GI Dynamics and Prana were up more than one percent; with Cochlear, CSL, Heartware, Psivida and Starpharma up by less than one percent.

Impedimed led the falls, down 1.5 cents or 13.0 percent to 10 cents with 101,394 shares traded.

Prima lost 8.7 percent; Pharmaxis fell five percent; Reva and Viralytics fell four percent or more; Tissue Therapies was down 3.6 percent; Acrux, Bionomics and Sirtex were down more than one percent; with Medical Developments, Mesoblast, QRX and Resmed down by less than one percent.

## COMPUMEDICS

Compumedics says it has secured a French Government EUR200,000 (\$A285,400) grant to develop sleep diagnostics with features specific to the French.

Compumedics said that the grant was in association with an unnamed “key opinion leader in sleep diagnostics in France”

The company said that sleep diagnostics in France had annual sales EUR30 million and the country was a key growth opportunity.

Compumedics said that it has had a permanent sales representative in France for the past three years.

The company said it had appointed a sales representative in Germany to focus specifically on its neuro-diagnostic products, including long-term epilepsy monitoring.

Compumedics said that the German market for neuro-diagnostic products was estimated at EUR100 million a year.

Compumedics executive chairman Dr David Burton said that after a lengthy period “securing the funding needed to ship all its orders, now in process, I am pleased to announce these new milestone achievements which will underpin new opportunities for growth”.

“The European medical devices markets remain viable opportunities for growth, despite the economic conditions there and particularly with the recent favorable movements in exchange rates,” Dr Burton said.

“Germany and France are some of the biggest individual markets in Europe, and they continue to offer significant upside for growth for the company,” Dr Burton said.

“As such, achieving these milestones are concrete steps forward in delivering on this growth opportunity,” Dr Burton said.

Compumedics was untraded at 5.8 cents.

## MEDICAL AUSTRALIA

Medical Australia shareholders have overwhelmingly voted on three resolutions relating to the merger with Sydney-based Medivet Pty Ltd (BD: Jun 6, 12, 2013).

Medical Australia said the extraordinary general meeting supported the 10-for-one share consolidation, the issue of 16,666,667 post-consolidation shares to Medivet and the placement of 40,000,000 post-consolidation shares at 30 cents each to raise \$12 million to fund the merger and further research, development and commercialization.

The consolidation resolution was passed with 280,237,404 proxy votes in favor and 714,465 votes against, while the share issue resolutions were supported by 269,348,515 votes (95.9%) in favor and 11,603,041 votes (4.1%) against.

In its last Appendix 3B statement, Medical Australia said it had 453,925,832 shares on issue, meaning the votes against the resolutions represent 2.6 percent of all shares.

In June, Medical Australia said that Medivet had revenue from multiple sources, including the set-up of stem-cell facilities, cryo-preservation of stem-cells for use in later life, ongoing supply of stem-cell equipment and a range of regenerative medicine products for the animal health market.

Medical Australia chief executive officer Mark Donnison said at that time that when the merger was completed “we will be the only profitable listed stem cell company in the world”.

“There are no other listed stem cell animal health companies,” Mr Donnison said in June. Medical Australia was unchanged at 1.5 cents.

## OBJ

OBJ says it has a clinical evaluation and exclusivity agreement with Glaxosmithkline Consumer Healthcare for a human clinical trial of a new toothbrush.

OBJ said it granted Glaxosmithkline “an exclusive right to conduct the study and to negotiate future licencing terms and conditions in consideration for GSK funding the clinical trial plus OBJ’s costs and expenses in supporting the trial”.

The company said the study would be the largest undertaken in the area of oral healthcare using its field-in-motion (FIM) microarray technology.

OBJ said that Glaxosmithkline would conduct the study and it would providing the technology and technical support.

The company said it had been working with Glaxosmithkline on the toothbrush technology for five years and it had developed specific magnetic microarrays for the three major commercial tooth care areas of anticaries or decay, hyper-sensitivity or sensitive teeth and remineralization or re-hardening.

OBJ said a small Glaxosmithkline-funded pilot study in 2012 led to this major human efficacy study, to be conducted Glaxosmithkline in Middlesex, England.

The company said that the study was expected to begin by the end of 2013.

OBJ was up 0.1 cents or 7.7 percent to 1.4 cents with 4.1 million shares traded.

## BIONICHE LIFE SCIENCES

Bioniche says that seven European countries will register its Folltropin follicle stimulating hormone to super-ovulate reproductively mature cattle.

Bioniche said that Austria, the Czech Republic, Denmark, Finland, France, Germany and Poland had approved the product with marketing authorizations issued in Austria, Denmark, France and Germany.

Bioniche was untraded at 30 cents.

## CELLMID

Cellmid has appointed Jillian McGregor as joint company secretary effective from today.

Cellmid said that Ms McGregor would work with existing company secretary Nicholas Falzon.

The company said that Ms McGregor advised companies and directors on regulatory compliance and corporate legal matters and had spent more than 15 years working as a corporate lawyer in commercial law firms.

Cellmid said that Ms McGregor was recently appointed as company secretary of Oncosil Medical and held Bachelor degrees in Commerce and Law from the University of New South Wales.

Cellmid was up 0.1 cents or 3.1 percent to 3.3 cents with 4.8 million shares traded.